Neuromonics Inc, Bethlehem, Pa, has issued a clinical summary of results from its most recent Neuromonics Tinnitus Treatment’s clinical efficacy research. The summary is derived from papers presented in peer-reviewed medical journals.
The summary provides details on three clinical trials involving 555 patients who demonstrated a consistent clinical benefit that persisted to 12 months in suitable patients. These results were published in Ear Nose & Throat Journal; Ear and Hearing; Annals of Otology, Rhinology, and Laryngology; and Trends in Amplification.
In addition to clinical results, the summary outlines nine additional studies that researchers have presented at medical meetings throughout the United States and Europe. Each provides additional evidence of clinical efficacy.
Neuromonics manufactures and distributes the clinically administered and monitored Neuromonics Tinnitus Treatment, which uses a non-invasive device that is customized to each patient’s individual audiological profile and delivers a neural stimulus that targets the brain’s auditory pathways.